In patients with melanoma, IT or peritumoral injection of recombinant GM-CSF results in an increase in the number of DCs in treated tumor lesions but this did not always result in better anti-tumor responses and effects on progression free survival (149, 153–155). Here, CSF2 is linked to neoplasm.